Mandate

Vinge has advised GeneraLife in connection with its acquisition of Livio Group

Vinge has advised GeneraLife, one of Europe's largest fertility clinic groups and owned by KKR, in connection with its acquisition of Livio Group.

Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway and Iceland. The acquisition also encompasses the Livio's own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark.

Vinge's team consisted of responsible partner Matthias Pannier and associates, Samra Baytar, Stina Bengtsson, Olivia Belding, Elias Bohlin (M&A), Trine Osen Bergqvist, Johan Wahlbom, Jakob Jeanrond, Victoria Fredén, Alva Chambert (Antitrust), Christoffer Nordin, Mika Jordan (Regulatory & Agreements), Rebecka Målquist (IP), Frida Ställborn, Karolina Cohrs (Real Estate), Calle Tengwall Pagels (Banking & Finance), Gustav Lindgren (Employment), Karolina Fuhrman (IT & GDPR) and Jessica Henning (Project Assistance).

Related

Vinge advises Revivo Group on the acquisition of Premator

Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers of Berg Propulsion

Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026